News – Page 1086 – Endpoints News

Say it with us: IQVIA is the new Quintiles and IMS Health

8 years ago

Visualize: Just how much did biotech unicorn Moderna rely on immigrants to build the staff?

8 years ago

Amgen is shaking up R&D (again), chopping 200 as Genentech targets 130 layoffs

8 years ago

Novartis pitches two new CAR-T applications to EMA; J&J reports positive data for lupus program

8 years ago

Valeant hands off its controversial, $1B female libido drug to Sprout backers in sweetheart deal

8 years ago

Bill Gates and rich allies help fund an alt-biotech startup path for the gene expression experts at Exicure

8 years ago

For 3rd time, the FDA and its new commissioner dropped safety issues and trial demands, clearing the path for snubbed ...

8 years ago

Two years in, the team at NousCom bags $49M to fund first human studies of neoantigen drugs

8 years ago

Shooting for a new standard on osteoarthritis, Merck KGaA outlines promising data for a potential game-changer

8 years ago

Peer Review: aTyr promotes data expert Sanjay Shukla as CEO

8 years ago

Former Puma exec agrees to prison time, penalty on insider trading case; Ex-GSK boss Witty to lead UK’s new ...

8 years ago

Feds charge Osiris execs with cooking the books as stock price soared

8 years ago

GSK R&D chief Vallance is out as its new CEO changes direction under a new crew

8 years ago

Is Neurocrine primed for takeover? Revenue soars on Ingrezza sales

8 years ago

Novartis and Amgen launch new Alzheimer's study

8 years ago

Valeant finally wins long-delayed FDA OK for its glaucoma drug, which is more good news for Aerie

8 years ago

GOP tax reform bill would repeal orphan drug research credits

8 years ago

Prize fight in Paris: Alnylam and Ionis slug it out over PhIII data in preparation for a blockbuster showdown

8 years ago

Focusing on next-gen cancer drugs, GSK touts a ‘breakthrough’ at FDA; Aisling raises $280M fund

8 years ago

IPO market warms with Spero, Allena heading to Wall Street

8 years ago

Sanofi scraps a PhII IL4/IL13 development program for lung scarring disease

8 years ago

Mallinckrodt bags another microcap biotech, picking up Ocera’s failed drug in $117M buyout

8 years ago

Dicerna and Boehringer partner on RNAi treatment for NASH

8 years ago

AveXis offers compelling reasons for a fast FDA OK for gene therapy to treat spinal muscular atrophy in infants

8 years ago

First page Previous page 1083 1084 108510861087 1088 1089 Next page Last page